Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan M Brotchie

Showing results (41-50 of 127) with videos related to

Pageof 13
Sort By:
Current Neurology and Neuroscience Reports|June 12, 2009
New insights into the organization of the basal gangliaJames B Koprich, Tom H Johnston, Philippe Huot, et al.
Molecular Neurodegeneration|October 30, 2010
Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's diseaseJames B Koprich, Tom H Johnston, M Gabriela Reyes, et al.
Neuropharmacology|June 15, 2015
The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaquePhilippe Huot, Tom H Johnston, Susan H Fox, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 9, 2002
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystoniaSusan H Fox, Mark Kellett, A Peter Moore, et al.
Pharmacological Reviews|January 16, 2013
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Neuropharmacology|June 23, 2012
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Experimental Neurology|January 15, 2005
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's diseaseTom H Johnston, Joohyung Lee, Jordi Gomez-Ramirez, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 17, 2010
Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's diseaseTom H Johnston, Susan H Fox, Matthew J McIldowie, et al.
European Journal of Pharmacology|July 13, 2015
The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells--The potential of JNX1001 as a therapeutic agentHelena K Kim, Karina M Mendonça, Patrick A Howson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 9, 2010
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primatesTom H Johnston, Susan H Fox, Matthew J Piggott, et al.
Pageof 13

Showing results (41-50 of 127) with videos related to

Sort By:
Pageof 13
Current Neurology and Neuroscience Reports|June 12, 2009
New insights into the organization of the basal gangliaJames B Koprich, Tom H Johnston, Philippe Huot, et al.
Molecular Neurodegeneration|October 30, 2010
Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's diseaseJames B Koprich, Tom H Johnston, M Gabriela Reyes, et al.
Neuropharmacology|June 15, 2015
The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaquePhilippe Huot, Tom H Johnston, Susan H Fox, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 9, 2002
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystoniaSusan H Fox, Mark Kellett, A Peter Moore, et al.
Pharmacological Reviews|January 16, 2013
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Neuropharmacology|June 23, 2012
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Experimental Neurology|January 15, 2005
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's diseaseTom H Johnston, Joohyung Lee, Jordi Gomez-Ramirez, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 17, 2010
Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's diseaseTom H Johnston, Susan H Fox, Matthew J McIldowie, et al.
European Journal of Pharmacology|July 13, 2015
The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells--The potential of JNX1001 as a therapeutic agentHelena K Kim, Karina M Mendonça, Patrick A Howson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 9, 2010
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primatesTom H Johnston, Susan H Fox, Matthew J Piggott, et al.
Pageof 13